Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Show more
Location: 1280 Rancho Conejo Blvd, Thousand Oaks, CA, 91320, United States | Website: https://www.atarabio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
88.7M
52 Wk Range
$5.00 - $18.70
Previous Close
$12.63
Open
$12.64
Volume
21,633
Day Range
$12.42 - $12.80
Enterprise Value
83.91M
Cash
22.32M
Avg Qtr Burn
-15.98M
Insider Ownership
21.29%
Institutional Own.
45.69%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tabelecleucel (tab-cel® or Ebvallo™) Details Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) | PDUFA Approval decision | |
ATA3219 Details Systemic lupus erythematosus, Lupus nephritis, Autoimmune disease | Failed Discontinued | |
ATA3219 Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Failed Discontinued | |
ATA188 Details Multiple sclerosis, Epstein-Barr virus | Failed Discontinued |